A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition

  • Paroxysmal Nocturnal Hemoglobinuria
Trial Status:

Active, not recruiting

This trial runs in
Cities
  • chang-chun-shi
  • cheng-du-shi
  • guang-zhou-shi
  • tian-jin-shi
  • Tianjin
  • wu-han-shi
Trial Identifier:

NCT04654468 YO42311

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This study will enrol participants aged 12 years or older with a body weight >= 40 kg diagnosed with PNH who have not been previously treated with complement inhibitor therapy. Approximately 50 participants will be treated with Crovalimab for at least 24 weeks.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT04654468 , YO42311 Trial Identifier
      Crovalimab Treatments
      Paroxysmal Nocturnal Hemoglobinuria Condition
      Official Title

      A Phase III, Multicenter, Single Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition

      Eligibility Criteria

      All Gender
      ≥12 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Body weight >= 40 kg at screening.
      • Willingness and ability to comply with all study visits and procedures.
      • Documented diagnosis of PNH, confirmed by high sensitivity flow cytometry.
      • Lactate Dehydrogenase Levels >= 2x the upper limit of normal (ULN) at screening.
      • Participants who have at least four transfusions during 12 months prior to screening (documented in the medical record).
      • Presence of one or more of the following PNH-related signs or symptoms within 3 months of screening.
      • Vaccination against Neisseria meningitidis < 3 years prior to initiation of study treatment or within 7 days after the first drug administration.
      • Vaccination against Haemophilius influenzae type B and Streptococcus pneumonia according to national vaccination recommendations.
      • For participants receiving other therapies (e.g., immunosuppressants, corticosteroids): stable dose for >= 28 days prior to screening and up to the first drug administration.
      • Adequate hepatic and renal function.
      • Women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception during the treatment period and for 6 months after the final dose of crovalimab.
      Exclusion Criteria
      • Current or previous treatment with a complement inhibitor.
      • History of allogeneic bone marrow transplantation.
      • History of Neisseria meningitidis infection within 6 months prior to screening and up to first drug administration.
      • Known or suspected immune or hereditary complement deficiency.
      • Known HIV infection with CD4 count < 200 cells/µl within 24 weeks prior to screening.
      • Infection requiring hospitalization or treatment with intravenous (IV) antibiotics within 28 days prior to screening and up to the first drug administration, or oral antibiotics within 14 days prior to screening and up to the first drug administration.
      • Active systemic bacterial, viral, or fungal infection within 14 days before first drug administration.
      • Presence of fever (>= 38˚C) within 7 days before the first drug administration.
      • Splenectomy < 6 months before screening.
      • History of malignancy within 5 years prior to screening and up to the first drug administration.
      • Pregnant or breastfeeding, or intending to become pregnant during the study or within 6 months after the final dose of study treatment.
      • Participation in another interventional treatment study with an investigational agent or use of any experimental therapy within 28 days of screening or within 5 half-lives of that investigational product, whichever is greater.

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now